Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2013, with the announcement issued on December 16, 2013. The filing details a strategic corporate action: a Voluntary Open Offer to increase GSK's ownership stake in its Indian pharmaceuticals subsidiary, GlaxoSmithKline Pharmaceuticals Limited, from 50.7% to up to 75%.
Key Financial Metrics and Transaction Details
- Transaction Value: Approximately INR 64 billion (approx. £629 million).
- Offer Price: INR 3,100 per share, representing a 26% premium to the closing share price on December 13, 2013.
- Shares to be Acquired: Up to 20,609,774 shares (24.3% of total outstanding shares).
- Subsidiary Performance (FY ended Dec 31, 2012):
- Turnover: INR 26 billion (approx. £313 million).
- Profit Before Tax: INR 9.8 billion (approx. £116 million).
- Profit After Tax and Exceptional Items: INR 5.6 billion (approx. £66 million).
- Funding: To be funded through GSK's existing cash resources.
Material Changes and Strategic Impact
The primary material change is the increase in GSK's exposure to the Indian pharmaceutical market. The transaction is designed to comply with Indian securities regulations requiring a minimum 25% public shareholding while allowing GSK to consolidate its control. The filing notes that the Indian subsidiary's share price appreciated 19% over the 12 months preceding the announcement.
Guidance, Outlook, and Accounting Treatment
- Earnings Impact: Management states the transaction will be earnings neutral in the first year and accretive thereafter.
- Capital Allocation: The deal will not impact expectations for the Group's long-term share buyback programme.
- Accounting: GSK will continue to consolidate 100% of the subsidiary's results. No gain or loss will be recorded on the acquisition; entries will be made to non-controlling interests and shareholders' equity, reducing the share of profits due to non-controlling interests.
- Timeline: Subject to regulatory clearance, the offer period is expected to begin in February 2014.
Investor Verification Checklist
- Verify the final acceptance rate of the Voluntary Open Offer to confirm the exact post-transaction ownership percentage.
- Confirm regulatory clearance from the Securities and Exchange Board of India (SEBI) and relevant stock exchanges.
- Monitor the actual impact on GSK's consolidated cash flow and liquidity in the first quarter of 2014 following the payment for shares.
- Review the detailed public statement and letter of offer filed with SEBI for specific terms and conditions.